2024
Cost-effectiveness and health impact of screening and treatment of Mycobacterium tuberculosis infection among formerly incarcerated individuals in Brazil: a Markov modelling study
van Lieshout Titan A, Klaassen F, Pelissari D, de Barros Silva J, Alves K, Alves L, Sanchez M, Bartholomay P, Johansen F, Croda J, Andrews J, Castro M, Cohen T, Vuik C, Menzies N. Cost-effectiveness and health impact of screening and treatment of Mycobacterium tuberculosis infection among formerly incarcerated individuals in Brazil: a Markov modelling study. The Lancet Global Health 2024, 12: e1446-e1455. PMID: 39151980, DOI: 10.1016/s2214-109x(24)00221-3.Peer-Reviewed Original ResearchConceptsDisability-adjusted life yearsTuberculosis preventive treatmentTuberculosis deathsHealth impactsImpact of screeningIntervention cost-effectivenessInfection screeningCost-effectiveNational Institutes of HealthHealth outcomesHealth gainsInstitutes of HealthQuantify health effectsTuberculosis casesCost-effectiveness ratioTreatment of Mycobacterium tuberculosis infectionPotential health impactsLife yearsGreater health benefitsTuberculosis preventionTarget populationMonths of isoniazidMarkov modelling studiesHealth statesHealth
2023
Tabby2: a user-friendly web tool for forecasting state-level TB outcomes in the United States
Swartwood N, Testa C, Cohen T, Marks S, Hill A, Beeler Asay G, Cochran J, Cranston K, Randall L, Tibbs A, Horsburgh C, Salomon J, Menzies N. Tabby2: a user-friendly web tool for forecasting state-level TB outcomes in the United States. BMC Medicine 2023, 21: 331. PMID: 37649031, PMCID: PMC10469407, DOI: 10.1186/s12916-023-02785-y.Peer-Reviewed Original ResearchConceptsLatent tuberculosis infectionTB outcomesDistrict of ColumbiaTreatment of LTBIIncremental cost-effectiveness ratioTB incidence rateTuberculosis disease burdenQuality-adjusted life yearsCost-effectiveness ratioPublic health agenciesTB casesTB preventionTB incidenceTuberculosis infectionTB epidemiologyDisease burdenIncidence rateService utilizationAdditional interventionsIncidence projectionsLife yearsDemographic dataSocietal perspectiveHealth agenciesPrevention approaches
2014
Modeling of Novel Diagnostic Strategies for Active Tuberculosis – A Systematic Review: Current Practices and Recommendations
Zwerling A, White RG, Vassall A, Cohen T, Dowdy DW, Houben RM. Modeling of Novel Diagnostic Strategies for Active Tuberculosis – A Systematic Review: Current Practices and Recommendations. PLOS ONE 2014, 9: e110558. PMID: 25340701, PMCID: PMC4207742, DOI: 10.1371/journal.pone.0110558.Peer-Reviewed Original ResearchConceptsNucleic acid amplification testsIncremental cost-effectiveness ratioActive tuberculosisHealth system modelDiagnostic strategiesNovel diagnostic strategiesAlternative nucleic acid amplification testsXpert MTB/RIFMTB/RIFCost-effectiveness ratioMulti-way sensitivity analysesFalse-negative diagnosesPre-diagnostic periodCost-effectiveness modelCost-effectiveness estimatesDiagnostic delayDiagnostic pathwayAdditional epidemiological dataTB diagnosticsEpidemiological dataReference listsAmplification testsEpidemiological impactEligible papersEpidemiological settingsAssessment of the patient, health system, and population effects of Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: an integrated modelling approach
Langley I, Lin HH, Egwaga S, Doulla B, Ku CC, Murray M, Cohen T, Squire SB. Assessment of the patient, health system, and population effects of Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: an integrated modelling approach. The Lancet Global Health 2014, 2: e581-e591. PMID: 25304634, DOI: 10.1016/s2214-109x(14)70291-8.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioHigh incremental costIncremental costLED fluorescence microscopyCost-effectiveness ratioPay thresholdsFull rolloutContext of TanzaniaCost-effective optionHealth policy formulationPolicy formulationDifferent diagnostic optionsIntegrated modelling approachModelling approachAdditional costHealth systemCostAlternative diagnosticsIntegrated modelXpert MTB/RIFPopulation effectsMTB/RIFPresumptive tuberculosis casesWillingnessUse of Xpert
2012
Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation
Menzies NA, Cohen T, Lin HH, Murray M, Salomon JA. Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation. PLOS Medicine 2012, 9: e1001347. PMID: 23185139, PMCID: PMC3502465, DOI: 10.1371/journal.pmed.1001347.Peer-Reviewed Original ResearchConceptsMultidrug-resistant TBCost-effectiveness ratioInitial diagnosisXpert MTB/RIF testMTB/RIF testXpert MTB/RIFIntroduction of XpertTB natural historyTB-HIV coinfectionMultidrug-resistant tuberculosisHigh HIV prevalenceMTB/RIFHealth system costsImplementation of XpertHealth impactsPopulation health impactCost-effectiveness resultsLong-term transmission dynamicsWorld Health OrganizationAntiretroviral therapyTB casesTB deathsTB morbidityHIV prevalenceRIF test